Gefurulimab (ALXN-1720) 是一种高亲和力、靶向补体蛋白 C5 的抗体抑制剂，可特异性结合 C5 并抑制其裂解为 C5a 和 C5b。Gefurulimab 能阻断补体末端通路激活，减少炎症损伤。Gefurulimab 能有效降低膜攻击复合物 (MAC) 形成，具有良好的药代动力学特性。Gefurulimab 可用于研究 IgA 肾病、狼疮性肾炎、重症肌无力等补体系统异常激活相关的肾脏和自身免疫性疾病。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) is 28.99 kDa.

Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) is 100.00%, determined by SEC-HPLC.

Gefurulimab bound to HSA protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Gefurulimab bound to HSA-Fc , and the EC50 was 0.006 nM.

Co-incubation of Gefurulimab with complement protein, then with the addition of Rituximab and Raji cells and incubated for 4 hours. CTG was used to detect the luciferase signal. As shown in fig, Gefurulimab can block rituximab-induced CDC killing, and the IC50 was 18.090 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.